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Figure 1. Probability of OS and DFS based on presence of EM disease
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71 S69CI, 30-37%) vs 33% (95% CI, 32 v 34%; p¼0.71). 5 y survivals
were 36% (95% CI, 32-39%) vs 35 (95% CI, 34-37%; p¼0.96;
Figure 1). In a univariate analysis, 5 y survival did not differ
by site of EM leukemia (CNS, skin only, lymph node only,
other vs no EM leukemia; p¼0.28) or by time EM leukemia
occurred (at diagnosis, vs at transplant; p¼0.27). There was
no signiﬁcant difference in the rate of relapse in persons with
or without EM leukemia based on intensity of pretransplant
conditioning. After myelo-ablative conditioning the relative
risk of relapse was 1.09 (95% CI, 0.95-1.24; p¼0.21) and for
RIC was 0.89 (95% CI, 0.70e1.14; p¼0.36).
Conclusions: We found no impact of pretransplant
EM leukemia on LFS or survival after allotransplant for
AML. These data suggest decisions regarding transplants
should be independent of whether or not there is EM
leukemia.Figure 1. Overall Survival and Relapse Free Survival71
Do Patients with High Risk or Relapsed Core Binding
Factor Acute Myeloid Leukemia Beneﬁt from Salvage
Allogeneic Stem Cell Transplantation?
Gabriela Hobbs 1, Ashwin Kishtagari 2, Patrick Hilden 3,
Juliet N. Barker 4, Ann A. Jakubowski 4,5,
Esperanza Papadopoulos 4, Sean Devlin 3, Farid Boulad 6,
Nancy Kernan 6, Rachel Kobos 6, Peter G. Steinherz 7,
Richard O’Reilly 6, Sergio A. Giralt 4, Martin Tallman 8,
Eytan Stein 9, Miguel-Angel Perales 4. 1Bone Marrow
Transplantat, Memorial Sloan-Kettering Cancer Center, New
York, NY; 2Leukemia Department, Memorial Sloan Kettering
Cancer Center, NY, NY; 3Department of Biostatistics and
Epidemiology, Memorial Sloan-Kettering Cancer Center, New
York, NY; 4Department of Medicine, Adult Bone Marrow
Transplant Service, Memorial Sloan-Kettering Cancer Center,
New York, NY; 5Bone Marrow Transplant, Memorial Sloan
Kettering Cancer Center, New York, NY; 6Department of
Pediatrics, Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center, New York, NY; 7Department of
Pediatrics, Memorial Sloan-Kettering Cancer Center, New York,
NY; 8Medicine/Leukemia Service, Memorial Sloan-Kettering
Cancer Center, New York, NY; 9Leukemia Service, Memorial
Sloan Kettering Cancer Center, NY, NY
Background: Acute myeloid leukemia (AML) associated with
inv(16), t(16;16), or t(8;21), known as core binding factor
(CBF) leukemias, are generally considered favorable risk.
However, relapse occurs in 30-40% of patients who achieve
ﬁrst complete remission (CR1). It is commonly assumed thatallogeneic hematopoietic stem cell transplantation (HCT) is
the preferred salvage strategy for relapsed disease, but there
are few data to support this clinical practice. To help guide the
practicing clinician, we retrospectively evaluated 67 consec-
utive patients with CBF-AML treated at a single institution
from 2000-2013 to evaluate the efﬁcacy of salvage HCT.
Patients and Methods: Of the 67 patients treated, 63
achieved a CR, 3 received supportive care and 1 died of
persistent disease. Five patients received a transplant in CR1
for high-risk features, including c-kit mutation (n¼3), ther-
apy-related AML (n¼1) and del-7q (n¼1). Thirty-two pa-
tients relapsed, with a median time to relapse of 11.6 months
(range 4.6-74.1 months), and 22 received salvage HCT in CR2
(n¼21) or refractory disease (n¼1). Reasons for not pro-
ceeding to salvage HCT included: infection (n¼3) or organ
toxicity (n¼1) precluding additional therapy, patient refusal
(n¼1) and lost to follow up (n¼4). One patient is undergoing
treatment with the goal to proceed to HCT. This report in-
cludes the 27 patients (median age 39 years, range 3-67.5)
who underwent HCT; patients received T-cell depleted (TCD)
graft (n¼17), double unit cord blood (DUCB, n¼5), DUCBwith
TCD-haploidentical donor graft (n¼2) or conventional graft
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71S70(n¼3). Adult donors were HLA-matched related (n¼9), HLA-
matched unrelated (n¼7), HLA-mismatched unrelated
(n¼4). Conditioning was myeloablative in 22 patients and
reduced intensity conditioning in 6.
Results: All patients except one engrafted. The rate of
grade II-IV acute graft-versus-host disease (GVHD) at 100
days was 26% (95%CI 11-44%). The rate of chronic GVHD at
2 years was 8% (95%CI 1-24%). The cumulative incidence of
relapse/progression and non-relapse mortality at 2 years
was 8% (95%CI 1-22%) and 12% (95%CI 3-29%), respectively.
As of July 2013, with a median follow-up among survivors
of 26 months (range 2-134 months), 22 of 27 HCT re-
cipients were alive; 2 died of relapse, 1 of GVHD and 2 of
multiorgan failure. At 2 years, OS for patients receiving a
HCT was 80% (95% CI 58-91%) and PFS was 80% (95%CI 58-
91%) (Figure 1).
Conclusions: Our data indicate that HCT represents an
important salvage therapy associated with extremely favor-
able outcomes for patients with relapsed CBF AML and for
those with high risk features at presentation. Additional
studies in larger patient cohorts are needed to determine the
optimal transplant strategy for this group of patients.Table 1
Patient Characteristics n, (%)
Age, median (range), years 58 (26-73)
Patient 55 years of older 30 Patients (54.5%)
Gender 27 Female, 28 Male
Donor type
Unrelated donor (MUD) 39 (71%)
Related donor (RD) 16 (29%)
Conditioning Regimen
Bu4Flu (FIC) 36 (65%)
Bu2Flu (RIC) 19 (35%)
Status at transplant
CR1 36 (65%)
CR2 5 (9%)
PIF 14 (35%)
CIBMTR risk
Low 39 (71%)
Intermediate 4 (7%)
PIF 14 (22%)
Cytogenetic risk
Low 33 (60%)
High 22 (40%)
CR¼complete remission, PIF¼primary refractory
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Introduction: Reduced and full intensity conditioning (RIC,
FIC) regimens employing intravenous (i.v.) busulfan plus
ﬂudarabine (Bu-Flu) have resulted in improved treatment
related mortality and comparable overall survival in patients
undergoing allogeneic HCT for AML/MDS who are not can-
didates for more intense regimens. However, relapse after
HCT remains a leading cause of treatment failure after such
conditioning regimens.
Methods: In Order to assess relapse following allogeneic HCT
for AML/MDS , a retrospective analysis was performed to
evaluate the outcomes of 55 consecutive patients with AML/
MDS (49/6) who received i.v. Bu-Flu based conditioning.
Blood samples were collected post HCT in a subset of those
patients (30 patients). Serum values of 42 biological markers
were measured at day 30 post HCT (2/30 patients were day
60 samples) using multiplex Luminex assay. Patients
characteristic are shown in Table-1. Patients received single
daily dose of iv Bu 3.2 mg/kg for 2 days (RIC, Bu2-Flu) or 4
days (FIC, Bu4-Flu) based on age, older or younger than 65
respectively. Fludarabine was given as a single daily dose of
40 mg/Kg for 4 days. Graft versus host disease prophylaxis
was Tacrolimus/Methotrexate in FIC recipients and
Tacrolimus/Mycophenolate in RIC recipients. Low dose thy-
moglobulin of 4.5 mg/kg was used in unrelated donor HCT
recipients.
Results: With a median follow up of 18 month, the overall
survival (OS) at 1 & 2 years was 736% and 67  7%,
respectively, (Fig 1). Similarly, disease free survival at 1 and 2
years was 64  7%. As expected, there was low cumulativeincidence of treatment related mortality of 8  3% at 1 and
2 years while the cumulative incidence of relapse was 28.0 
3% and 31 2% at 1 and 2 years respectively, (Fig 2). Cumu-
lative incidence of grade II-IV acute GVHD was 54% with
grade III-IV of 25% at day 100. Cumulative incidence of
chronic GVHD was 49, 54% at 1 and 2 years respectively. In a
subset of patients where chemokine analysis was performed
(30 patients), only MCP-1 levels at day 30 post HCT were
predictive of relapse out of the 42 biological markers tested.
The 7 out of 30 patients who relapsed in this subset (23%)
had higher mean level of MCP-1 at day 30 of 537, SD 213
versus 324, SD  160, P¼0.007, (Fig 3). MCP-1 was predictive
of leukemic relapse 82 days in advance on average prior to
overt hematological relapse. Full chimerism (>95%) was
detected at Day 30 in 5/7 patients who relapsed in the bio-
logical marker group.
Conclusion: Bu-Flu based conditioning regimens result in
improved OS in patients with AML/MDS but do not impact
relapse rate after allogeneic HCT. Serum MCP-1 levels in the
early post-transplant period were predictive of relapse in
subset of patients where post HCT biomarkers were avail-
able. Future larger studiesmay ﬁnd potential role ofMCP-1 in
